MDS Pharma Services Finds Suitor
Ricerca Biosciences
, LLC, announced today its execution of a purchase agreement to acquire the Discovery and Preclinical business of
MDS Pharma Services
with facilities in Bothell, Washington; Lyon, France; and Taipei, Taiwan. Company headquarters will remain in Concord, Ohio.
Ricerca Chairman and CEO Ian Lennox stated, “The addition of these facilities and personnel complement Ricerca’s existing facility in Concord, Ohio, and position us as a global, preferred provider of discovery and development services. We have intimate working knowledge of these facilities; all are steeped in decades of experience and expertise.”
The proposed transaction between the two organizations is subject to customary regulatory and closing conditions. The transaction is expected to close within the next two months.
About Ricerca Biosciences
Ricerca Biosciences currently has capabilities in discovery and medicinal chemistry, API process chemistry, cGMP manufacturing and scale-up and IND-enabling toxicology. The addition of the MDS Pharma Services molecular profiling, pharmacology/DMPK and drug safety assessment services will allow Ricerca to offer a more comprehensive suite of discovery and preclinical services to support drug candidates from discovery through IND on a global scale.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
